Novel Drug Discovery for the Treatment of Cancer

Welcome to Sentinel Oncology. Our aim is to discover new chemical entities for the use in better treatments for cancer.

Learn about our research and development

Become a Product Partner

Sentinel Oncology is seeking partners to out-license products from its oncology pipeline at the pre-clinical development phase.

The Sentinel pipeline contains a number of novel small molecule programmes designed to inhibit key targets important in cancer therapy including angiogenesis & invasion, DNA repair pathways and tumour hypoxia.

The CHK1 programme is currently undergoing pre-clinical evaluation following successful in-vivo proof of concept studies.

Contact us to find out more